Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents

We screened TP53 mutations in 168 MDS patients who were treated with HMA and evaluated predictive and prognostic value of TP53 mutations. Overall response to HMA was not different based on TP53 mutation status (45% vs. 32% in TP53-mutated and wild type [WT], respectively, P = 0.13). However, respons...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Oncotarget
Main Authors: Takahashi, Koichi, Patel, Keyur, Bueso-Ramos, Carlos, Zhang, Jianhua, Gumbs, Curtis, Jabbour, Elias, Kadia, Tapan, Andreff, Michael, Konopleva, Marina, DiNardo, Courtney, Daver, Naval, Cortes, Jorge, Estrov, Zeev, Futreal, Andrew, Kantarjian, Hagop, Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado: Impact Journals LLC 2016
Assuntos:
Research Paper
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC4924706/
https://ncbi.nlm.nih.gov/pubmed/26871476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7290
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares